Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers
Top Cited Papers
Open Access
- 1 March 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (3) , 958-966
- https://doi.org/10.1128/aac.01034-08
Abstract
A four-part, randomized, crossover study with healthy subjects evaluated the effects of gastric pH, the dosing frequency and prandial state, food consumption timing, and gastric motility on the absorption of posaconazole. In part 1, a single dose (SD) of posaconazole (400 mg) was administered alone or with an acidic beverage or a proton pump inhibitor (PPI), or both. In part 2, posaconazole (400 mg twice daily and 200 mg four times daily) was administered for 7 days with and without a nutritional supplement (Boost). In part 3, an SD of posaconazole (400 mg) was administered while the subjects were fasting and before, during, and after a high-fat meal. In part 4, an SD of posaconazole (400 mg) and the nutritional supplement were administered alone, with metoclopramide, and with loperamide. Compared to the results obtained with posaconazole alone, administration with an acidic beverage increased the posaconazole maximum concentration in plasma (Cmax) and the area under the concentration-time curve (AUC) by 92% and 70%, respectively, whereas a higher gastric pH decreased the posaconazole Cmax and AUC by 46% and 32%, respectively. Compared to the results obtained with posaconazole alone, posaconazole at 400 mg or at 200 mg plus the nutritional supplement increased the posaconazole Cmax and AUC by 65% and 66%, respectively, and by up to 137% and 161%, respectively. Administration before a high-fat meal increased the Cmax and the AUC by 96% and 111%, respectively, while administration during and after the meal increased the Cmax and the AUC by up to 339% and 387%, respectively. Increased gastric motility decreased the Cmax and the AUC by 21% and 19%, respectively. Strategies to maximize posaconazole exposure in patients with absorption difficulties include administration with or after a high-fat meal, with any meal or nutritional supplement, with an acidic beverage, or in divided doses and the avoidance of proton pump inhibitors.Keywords
This publication has 40 references indexed in Scilit:
- Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal InfectionAntimicrobial Agents and Chemotherapy, 2007
- Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2007
- A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2007
- In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2006
- Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- Oral Bioavailability of Posaconazole in Fasted Healthy SubjectsClinical Pharmacokinetics, 2005
- PosaconazoleDrugs, 2005
- Antacids RevisitedDrugs, 1999
- Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic MycosesClinical Pharmacokinetics, 1997